168 related articles for article (PubMed ID: 38072761)
1. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis.
Gomez-Veiga F; Szmulewitz RZ; Holzbeierlein J; Azad AA; Iguchi T; Villers A; Alcaraz A; Alekseev B; Shore ND; Rosbrook B; Zohren F; Ma J; Haas GP; Stenzl A; Armstrong AJ
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38072761
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
[TBL] [Abstract][Full Text] [Related]
3. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Azad AA; Armstrong AJ; Alcaraz A; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):274-282. PubMed ID: 34420037
[TBL] [Abstract][Full Text] [Related]
5. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Gravis G; Boher JM; Joly F; Soulié M; Albiges L; Priou F; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Culine S; Mourey L; Beuzeboc P; Habibian M; Oudard S; Fizazi K;
Eur Urol; 2016 Aug; 70(2):256-62. PubMed ID: 26610858
[TBL] [Abstract][Full Text] [Related]
7. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Armstrong AJ; Azad AA; Iguchi T; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Alcaraz A; Alekseev B; Shore ND; Gomez-Veiga F; Rosbrook B; Zohren F; Yamada S; Haas GP; Stenzl A
J Clin Oncol; 2022 May; 40(15):1616-1622. PubMed ID: 35420921
[No Abstract] [Full Text] [Related]
8. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
9. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Stenzl A; Szmulewitz RZ; Petrylak D; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Gomez-Veiga F; Ivanescu C; Rosbrook B; Ramaswamy K; Ganguli A; Haas GP; Armstrong AJ
Prostate; 2022 Sep; 82(13):1237-1247. PubMed ID: 35675470
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
[TBL] [Abstract][Full Text] [Related]
12. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy for high-volume
Jian T; Zhan Y; Yu Y; Yu K; Hu R; Wang J; Lu J
Front Pharmacol; 2023; 14():1148021. PubMed ID: 37153773
[No Abstract] [Full Text] [Related]
14. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
[TBL] [Abstract][Full Text] [Related]
15. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.
Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B
Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Iguchi T; Kimura G; Fukasawa S; Suzuki H; Uemura H; Nishimura K; Matsumoto H; Yokomizo A; Armstrong AJ; Rosbrook B; Sugg J; Baron B; Chen L; Kunieda F; Stenzl A
Int J Urol; 2021 Jul; 28(7):765-773. PubMed ID: 33955599
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED).
Sentana-Lledo D; Chu X; Jarrard DF; Carducci MA; DiPaola RS; Wagner LI; Cella D; Sweeney CJ; Morgans AK
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38688766
[TBL] [Abstract][Full Text] [Related]
18. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
[TBL] [Abstract][Full Text] [Related]
19. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
Bitting RL; Healy P; George DJ; Anand M; Kim S; Mayer T; Winters C; Riggan C; Rasmussen J; Wilder R; Stein M; Frizzell B; Harrison MR; Zhang T; Lee WR; Wu Y; Koontz BF; Armstrong AJ
Eur Urol Oncol; 2021 Dec; 4(6):948-954. PubMed ID: 32063492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
